Anika Therapeutics, Inc.

DB:AKP Stock Report

Market Cap: €240.4m

Anika Therapeutics Future Growth

Future criteria checks 3/6

Anika Therapeutics's revenue is forecast to decline at 13.3% per annum while its annual earnings are expected to grow at 108.3% per year. EPS is expected to grow by 108.3% per annum. Return on equity is forecast to be 4.2% in 3 years.

Key information

108.3%

Earnings growth rate

108.3%

EPS growth rate

Biotechs earnings growth42.4%
Revenue growth rate-13.3%
Future return on equity4.2%
Analyst coverage

Low

Last updated01 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:AKP - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026124510252
12/31/2025115-36202
12/31/2024150-39-282
9/30/2024164-98-17N/A
6/30/2024167-7419N/A
3/31/2024169-77-42N/A
12/31/2023167-83-7-2N/A
9/30/2023163-25-11-5N/A
6/30/2023162-22-16-9N/A
3/31/2023157-22-53N/A
12/31/2022156-15-34N/A
9/30/2022152-1628N/A
6/30/2022152-1128N/A
3/31/2022150-239N/A
12/31/2021148438N/A
9/30/2021145-627N/A
6/30/2021137-13710N/A
3/31/2021129-27810N/A
12/31/2020130-241113N/A
9/30/2020128-42224N/A
6/30/2020126112628N/A
3/31/2020125282730N/A
12/31/2019115273437N/A
9/30/2019112313134N/A
6/30/2019109293135N/A
3/31/2019109303134N/A
12/31/2018106193035N/A
9/30/2018108192532N/A
6/30/201810818N/A33N/A
3/31/201811120N/A35N/A
12/31/201711332N/A41N/A
9/30/201711332N/A40N/A
6/30/201711134N/A39N/A
3/31/201710431N/A32N/A
12/31/201610333N/A24N/A
9/30/201610636N/A34N/A
6/30/201610335N/A31N/A
3/31/201610034N/A43N/A
12/31/20159331N/A40N/A
9/30/20158528N/A39N/A
6/30/20158425N/A37N/A
3/31/20158727N/A30N/A
12/31/201410638N/A40N/A
9/30/201410437N/A33N/A
6/30/20149936N/A33N/A
3/31/20149433N/A33N/A
12/31/20137521N/A25N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AKP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).

Earnings vs Market: AKP is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: AKP is expected to become profitable in the next 3 years.

Revenue vs Market: AKP's revenue is expected to decline over the next 3 years (-13.3% per year).

High Growth Revenue: AKP's revenue is forecast to decline over the next 3 years (-13.3% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: AKP's Return on Equity is forecast to be low in 3 years time (4.2%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y